Exome, transcriptome and miRNA analysis don’t reveal any molecular markers of TKI efficacy in primary CML patients

Table 5 Characteristics of patients for miRNA study

Patient	Gender	Age, years	Sokal score	TKI first line, dosage	Efficient TKI
3	Female	57	Low risk	Imatinib, 400 mg	Optimal response
5	Female	68	Intermediate risk	Imatinib, 400 mg	Non-optimal response
7	Male	34	Intermediate risk	Imatinib, 400 mg	Non-optimal response
12	Female	38	Low risk	Imatinib, 400 mg	Optimal response
13	Female	26	Low risk	Imatinib, 400 mg	Optimal response
14	Male	56	Low risk	Imatinib, 400 mg	Optimal response
15	Female	65	Low risk	Imatinib, 400 mg	Optimal response
16	Female	32	High risk	Imatinib, 400 mg	Optimal response
17	Male	44	Low risk	Imatinib, 400 mg	Non-optimal response
18	Female	89	Low risk	Imatinib, 400 mg	Non-optimal response
19	Female	63	Intermediate risk	Imatinib, 400 mg	Non-optimal response
20	Male	49	Intermediate risk	Imatinib, 400 mg	Non-optimal response

ISSN: 1755-8794